Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer’s Disease: A Review of Clinical Trials
Table 1
Inclusion and exclusion criteria of papers selected for this review.
Criterion
Reason of inclusion
Reason of exclusion
Population
Qualifying disease: AD (diagnosed with established criteria, e.g., DSM-IV and NINCDS-ADRDA) Any severity of disease at baseline Community-/nursing-home-dwelling residents
Perspective of the study
Prospective (concurrent) Comparative
Retrospective (nonconcurrent, historical)
Type of the study
RCT (open label or blinded) Crossover trials with a washout period between treatments
Non-randomised CCT: cohort observational case control cross sectional noncomparative study
Language
English
All others
Study duration
Any
None
Sample size
Any
None
Intervention/treatments
Any dose of (i) donepezil (ii) memantine
Control intervention/treatments
Placebo/usual care Any of the above interventions
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders; NINCDS-ADRDA: National Institute of Neurological and Communicative Disorders and Stroke and the AD and Related Disorders Association; CCT: controlled clinical trial.
